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Abstract
Background: In 2007, the National Cancer Institute (NCI) launched the NCI Community Cancer Centers Program
(NCCCP) as a public-private partnership with community hospitals with a goal of advancing cancer care and
research. In order to leverage federal dollars in a time of limited resources, matching funds from each participating
hospital were required. The purpose of this paper is to examine hospitals’ level of and rationale for co-investment in
this partnership, and whether there is an association between hospitals’ co-investment and achievement of
strategic goals.
Methods: Analysis using a comparative case study and micro-cost data was conducted as part of a comprehensive
evaluation of the NCCCP pilot to determine the level of co-investment made in support of NCI’s goals. In-person or
telephone interviews with key informants were conducted at 10 participating hospital and system sites during the
first and final years of implementation. Micro-cost data were collected annually from each site from 2007 to 2010.
Self-reported data from each awardee are presented on patient volume and physician counts, while secondary data
are used to examine the local Medicare market share.
Results: The rationale expressed by interviewees for participation in a public-private partnership with NCI included
expectations of increased market share, higher patient volumes, and enhanced opportunities for cancer physician
recruitment as a result of affiliation with the NCI. On average, hospitals invested resources into the NCCCP at a level
exceeding $3 for every $1 of federal funds. Six sites experienced a statistically significant change in their Medicare
market share. Cancer patient volume increased by as much as one-third from Year 1 to Year 3 for eight of the sites.
Nine sites reported an increase in key cancer physician recruitment.
Conclusions: Demonstrated investments in cancer care and research were associated with increases in cancer
patient volume and perhaps in recruitment of key cancer physicians, but not in increased Medicare market share.
Although the results reflect a small sample of hospitals, findings suggest that hospital executives believe there to
be a strategic case for a public-private partnership as demonstrated through the NCCCP, which leveraged federal
funds to support mutual goals for advancing cancer care and research.
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Background
Cancer is a complex disease that requires broad engage-
ment of various clinical specialists and organizations to
develop a patient-centered delivery system that inte-
grates scientific discovery and provides highly coordi-
nated, evidence-based multi-specialty care across the
care continuum. While these systems are well-
established in many of the largest cancer centres in the
United States, not all patients have access to these cen-
tres. Rather, the majority of cancer patients in the United
States receive care in their local communities. To pro-
mote access to the same high-quality care for patients,
regardless of residence, the National Cancer Institute
(NCI), one of the 27 institutes of the National Institutes
of Health, designed the Community Cancer Centers Pro-
gram (NCCCP) pilot as a public-private partnership to
accelerate the diffusion of the latest science to local
communities.* Correspondence: debra@rti.org1RTI International, 3040 E Cornwallis Rd, PO Box 12194, Research Triangle
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In a public-private partnership, government agencies
and private sector organizations share in the financing
and operations of a program or project to accomplish
important public goals [1,2]. In the case of the NCCCP,
the federally-funded NCI partnered with not-for-profit
community hospitals to share risk and cost, as well as
knowledge and capabilities to advance cancer care in six
key areas: disparities, clinical trials, biospecimens, infor-
mation technology, quality of care, and survivorship and
palliative care [3-5]. Through the NCCCP, the NCI
provided funding to eight community hospitals and two
multi-hospital systems, each operating a cancer program
and caring for at least 1,000 new cancer patients annu-
ally. Each site was awarded approximately US$ 500,000
per year to cover costs for specific deliverables related to
the NCCCP award. In addition to receiving federal
funds, each organization was expected to contribute in-
stitutional dollars (i.e. matching funds) to cover
NCCCP-related activities including redesigning care pro-
cesses and organizational structures; however, the
amount of matching funds was not specified.
The success of public-private partnerships such as the
NCCCP rests with the commitment of executive leaders
at private sector (non-government) organizations to in-
vest time and resources into the required activities.
However, challenges exist when resources are con-
strained, and financial benefits cannot be demonstrated.
Leatherman et al. [6] demonstrated the effects of finan-
cing misalignments on quality initiatives, defining the
concepts of the business, economic, and social cases for
quality of care. They argued that private sector organiza-
tions were unlikely to sustain quality improvement activ-
ities in the absence of a demonstrated business case:
either a short-term, positive financial return on an activity
or the expectation of positive changes to organizational
function and sustainability.
Previous studies examining quality improvement initia-
tives in cancer have focused on the business case [7,8],
and researchers have struggled to find hard evidence of a
quantifiable financial return on investment. However,
leaders continue to invest in clinical programs such as
cancer care, citing indirect benefits such as reputational
effects and the ability to provide access to cutting-edge
care. These sorts of qualitative considerations have been
shown to play a significant role in decision making around
investments by not-for-profit hospitals [8-11]. As a result,
the concept of a business case may not fully capture all of
the perceived benefits of an investment to improve a
cancer program. Therefore, for this study, we defined the
“strategic case” for NCCCP participation.
In our definition, the strategic case encompasses the
business, economic, and social cases and includes those
outcomes of greatest interest to the hospital executive
management. Strategic outcomes are those that drive
management decisions in how best to allocate program-
specific resources. This paper presents study findings
that explore (1) the extent to which hospital executive
management believed there to be a strategic case for
participation and the specific outcomes that comprised
the strategic case, (2) the level of investments made by
the participating hospitals, and (3) whether the total in-
vestments were associated with changes in the strategic
outcomes specified by hospital executive management.
Methods
NCI contracted with RTI International (RTI) to conduct
a comprehensive evaluation of the NCCCP pilot [12], in-
cluding a micro-cost study and a comparative case study
[5]. Although a total of 16 hospitals implemented the
NCCCP, only the 10 lead sites are the focus of the evalu-
ation findings reported herein. In addition to these com-
ponents of the independent evaluation, research projects
were conducted by leaders from the program [13-17], or
were added as evaluation methods [18,19].
Data collection and secondary sources
The evaluation collected data on NCCCP-related
spending as well as qualitative data from interviews
with hospital executive management to gain insights
into how executives view the financial and other (stra-
tegic) benefits associated with NCCCP participation
and how they weigh those benefits against the costs.
RTI conducted initial and follow-up interviews with
Chief Financial Officers (CFOs) by phone and with
Chief Executive Officers (CEOs) or Chief Operating
Officers (COOs) during site visits each year to partici-
pating hospitals. Selected anonymous quotes from these
interviews are presented in italics and identified as
being stated by a CFO or a CEO/COO during the
specified year of program implementation.a
Micro-cost data were collected each year on an Excel-
based input document called the Cost Assessment Tool
[20-22]. The tool was customized to capture spending
across three cost domains for each year of program im-
plementation: NCI-funded subcontract costs (invoiced
costs), costs underwritten by the sponsoring organization
(matching costs), and a valuation of donated time (do-
nated costs).b In addition to these primary data sources,
numerous secondary data sources were used to examine
elements of the context within which each site was operat-
ing. In this paper, we present findings from the following
secondary sources.
Assessment surveys
Annual surveys completed by each participating hospital
that collected variables such as unduplicated cancer
patient volume c and the number of key cancer physi-
cians that operate in the cancer centre or program.
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Medicare market share
The market of the NCCCP hospitals was defined as the
Core Based Statistical Area in which the hospital is
located and identification of other hospitals located
within the NCCCP markets obtained from the Annual
Survey of the American Hospital Association data. For
all hospitals in each NCCCP market, the total number of
Medicare discharges in the hospital during Fiscal Years
(FYs) 2006 and 2011 was determined using the “bills”
variable from the annual Medicare Inpatient Prospective
Payment System.d For each FY and each hospital market,
total Medicare discharges from market hospitals were
summed to determine the total number of Medicare
discharges. The NCCCP hospital’s share of Medicare
discharges was calculated as the proportion of the
market’s discharges that were from that hospital.
Analysis strategy
Qualitative data were coded and analysed using state-
of-the-art procedures to identify thematic findings
characterising the strategic outcomes valued by hos-
pital executives [23]. To assess levels of hospital co-
investment, micro-cost data were analysed using Stata
software and the methods described in the Economic
Evaluation Report [20]. To assess whether there were
changes over time in any of the three strategic out-
comes – patient volume, market share, and physician
recruitment – identified through the interviews, we
collected secondary data from the sources described
above and tested for statistically significant differences
between FY 2006 and FY 2011 using t-tests for
samples of equal variance. Finally, to assess whether
levels of investment were associated with performance
on any of the strategic outcomes, data for the three
outcomes were ranked according to the percent
change for a hospital site, specific to each variable.
This allowed consideration of the variation in starting
points for the hospitals. The percent change from FY
2006 to FY 2011 was rank ordered such that those
hospitals that were among the highest achievers
(compared to the other nine NCCCP sites) for that
outcome received a rank of 1, and the lowest received
a rank of 10. These ranks were then categorized as
either “high” for the top five sites or “low” for the
bottom five sites to explore patterns across sites on
how they performed on each outcome relative to their
total investments in the NCCCP.
In this paper, we first present perceptions of the stra-
tegic case as described by CFOs and CEOs or COOs,
and descriptive analysis of changes over time in the
three strategic outcomes. We then present overall cost
study data for each site across the 3 years of the pilot
program. Finally, we examine the extent to which the
three key strategic outcomes were achieved by the sites
(i.e. increases in Medicare market share, cancer patient
volume, and key cancer physicians) relative to hospital
investment levels.
Results
Relevant hospital characteristics
During the process of site selection for the NCCCP
pilot, NCI purposefully selected hospitals that had vary-
ing levels of development of their cancer programs or
service lines [3]. Several sites had limited capacity or
history with conducting clinical trials research, working
with disparate populations, and/or coordinating care
across the cancer continuum to ensure that patients
received evidence-based, timely care. Across the partici-
pating hospitals, the position of the cancer program
within the organizational structure also differed (Holden,
et al., 2012). For example, some hospitals had independ-
ent cancer service lines with a physician director report-
ing directly to hospital executive, whereas others were
much more fragmented organisationally. Eight of the
lead sites reported having a physician director for the
cancer centre or program as of 2007, with varying
degrees of time devoted to this position. All but two of
the 10 lead sites relied primarily on cancer physicians
working in private practices. All lead sites had to have at
least 1,000 new cancer patients in CY 2006 in order to
qualify for NCCCP [12].
Overview of top hospital management interview findings
and changes in outcomes
CEOs/COOs and CFOs tended to stress different rea-
sons for NCCCP participation. For example, CEOs/
COOs tended to emphasize how the program would
help them improve quality of cancer care and enhance
their image in cancer research and care, whereas CFOs
tended to emphasize how the program would help them
to become a leader in their local market. However, all
consistently agreed that there were four primary motiva-
tions that provide a strategic case for their involvement:
(1) increases in their market share for cancer care, par-
ticularly through the affiliation with NCI; (2) increases
in their patient volume and enhancement of their payer
mix; (3) recruitment of key cancer physicians; and (4)
increases in access to care and/or research for local
cancer patients. Although many sites found it difficult
to separate the effects of the NCCCP from other
efforts related to cancer care, virtually all CFOs
recognized the strategic fit of the NCCCP with qual-
ity improvement goals, and the reputational value of
formal affiliation with NCI. For example, two separate
CFOs commented:
“Volume growth, contribution to margin increase, and
recruitment of physicians and retention are things that
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we are tracking for our strategic program and for an
entire service line.” (CFO, Year 1)
“We also saw the NCI connection as a way to
differentiate ourselves from other community hospitals
out there who are competitors…” (CFO, Year 1)
Market share
As shown in Table 1, sites varied in the extent to which
they led their local market for Medicare patients as of
2006, ranging from 1.72% (Site 2), indicating a highly
competitive market, to 80.57% (Site 8), a market leader.
CFOs across the sites consistently viewed the NCCCP as
providing them with a mechanism for becoming a
market leader for cancer care:
“We are one of the leaders in the market from a
cardiology standpoint, surgical standpoint, and
orthopedic standpoint, but in oncology we are not.
That is one of the reasons why we are interested in
this particular program…We view these as important
value-added activities and view the payoff [as] coming
from the additional business that is provided…and
attracting the payer mix that will provide the funding
to do these kinds of things.” (CFO, Year 1)
“I think reputation and market share: those are
measures that show we are doing something right in
the community…” (CFO, Year 1)
As shown in Table 1, Medicare market share in 2011 for
the 10 lead sites had changed to some extent, ranging from
1.54% (Site 2) to 80.01% (Site 8). Over the 5-year period, six
sites experienced a statistically significant change in their
Medicare market share, although the increases cannot be
causally linked to the NCCCP.
Cancer patient volume
Becoming a market leader may not, in and of itself, be
sufficient to maintain the NCCCP beyond the funding
period, especially in the face of fiscal challenges. Respon-
dents noted that the strategic case for NCCCP participa-
tion also involved increasing patient volume, along with
enhancing their payer mix:
“[The NCCCP] has been a catalyst for us to raise
the bar. It drives growth. We want to have more
patients go through our program to show those
outcomes, because greater numbers prove a lot
more…” (CEO/COO, Year 1)
“Patients choosing to come here – because we offer
complete and state-of-the-art cancer care services –
is critical… We benefit financially from that,
because it is one of our more profitable service
lines.” (CFO, Year 1)
Although enhanced reputation is difficult to assess,
the overall evaluation did capture the extent to which
hospitals changed their cancer patient volume. Al-
though a causal link to NCCCP participation cannot
be established, data reported by sites in their initial
proposals for funding compared to their Final Assess-
ment Survey (specific to NCCCP) suggest the undu-
plicated cancer patient volume increased by about
one-third from Year 1 to Year 3 for four sites (percentage
increases of 29.1% to 36.8%); the remaining four sites
reported increases ranging from 1.9% to 20.1% (Table 2).
Table 1 Results of Medicare market share at baseline and follow-up of NCCCP implementation
Site numbera Medicare market
share (2006)b %
Medicare market
share (2011)c
Differences Ranking of
differencesd
Degree of
changee
Site 1 30.97 31.21 0.24 3 H
Site 2 1.72 1.54* −0.18 5 H
Site 3 46.54 45.60 −0.94 9 L
Site 4 50.61 54.60* 3.99 1 H
Site 5 15.45 14.69* −0.76 7 L
Site 6 8.85 8.93 0.08 4 H
Site 7 7.51 5.05* −2.46 10 L
Site 8 80.57 80.01 −0.56 6 L
Site 9 48.22 47.43 −0.79 8 L
Site 10 25.20 26.42* 1.22 2 H
*P <0.01.
aSites have been randomly numbered to ensure confidentiality of data.
bData Source: Medicare Provider of Service file.
cData Source: Medicare Provider of Service file.
d1 = highest positive change; 10 = lowest positive change or highest negative change.
eH = high degree of change; L = low degree of change.
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Sites 3 and 4 experienced a decrease in their cancer
patient volume during the course of the pilot (−18.3%
and −0.3%, respectively).
Key cancer physician recruitment
As the hospitals grew in their local reputations for cancer
care through NCCCP participation, the consistent hope
among hospital executive management was that this would
also enhance their ability to recruit key cancer physicians.
This enhanced recruitment would be performed through
their association with NCI and the obvious priority they
were placing on their cancer service line as well as through
their added capacity to conduct cancer research, something
that many noted was important to their physicians:
“The ability to recruit specialists is really important to
us, and we haven’t really tried to quantify that, but
that is important.” (CFO, Y1)
“The connection to NCI is very important. [It] helps us
recruit new physicians and helps us recruit excellent
nurses. People want to be a part of a special program.
The linkage is pretty compelling.” (CEO/COO, Year 3)
While full attribution to the NCCCP is not possible,
all but one site (Site 7) reported an increase in the
number of key cancer physicians available to their
program, with additions for the nine remaining hospi-
tals ranging from as high as 35 to as low as 1 (Table 3).
Anecdotally, we know that two hospitals recruited new
cancer physician directors during the first year of the
program, each of whom told us in later years that they
came to their hospital largely because of the NCI
connection and the NCCCP.
Micro-cost data findings
As revealed through the hospital executive management
interviews, site leaders recognized the need to invest in
the program and the components that were important
to NCI, committing to co-investment at the time of
program initiation. Across the 3 years of the pilot, the
10 lead sites reported a total of nearly US$ 37 million of
their own investment as matched to less than US$ 15
million received from NCI. In terms of donated costs,
sites reported a total of 78,634 hours. Reported donated
time varied across sites from less than 400 hours (Site 6)
to more than 24,000 hours (Site 8). The following
sections provide a summary of variations in the costs by
year and site.
Costs across pilot implementation Years 1–3
The NCCCP was very successful in leveraging govern-
ment dollars, both by direct site investment and by
donated services (Table 4). We define leverage as the
value of these co-investments (i.e. private funds)
expressed relative to the value of NCCCP funding (i.e.
public funds). Per dollar of NCCCP funds distributed
to sites, the overall leverage was US$ 36.8 million
across all 3 years of pilot implementation. Findings
indicate further that for every US$ 1 received by NCI
each year, sites invested a total of US$ 3.47 in Year 1,
US$ 3.66 in Year 2, and US$ 4.00 in Year 3, including
both matching and donated costs.
Co-investment by site
The biggest component of both matching and donated
costs reported by sites every year was physician time.
Although the share of total spending by cost domain
varied across sites, some sites showed more consistent
Table 2 Results of cancer patient volume at baseline and follow-up of NCCCP implementation
Total cancer patient volume
Site numbera Baseline (CY 2006)b Follow-up (CY 2009)c Net change Percent change (%) Ranking of changed Degree of changee
Site 1 1,057 1,400 343 32.4 3 H
Site 2 1,527 1,577 50 3.3 7 L
Site 3 2,591 2,116 475 −18.3 10 L
Site 4 1,429 1,424 −5 −0.3 9 L
Site 5 2,290 3,133 843 36.8 1 H
Site 6 2,863 3,133 280 9.8 6 L
Site 7 1,075 1,464 389 36.2 2 H
Site 8 1,379 1,781 402 29.1 4 H
Site 9 1,236 1,484 248 20.1 5 H
Site 10 2,595 2,645 50 1.9 8 L
aSites have been randomly numbered to ensure confidentiality of data.
bData Source: Initial Request for Proposals responses from sites for Calendar Year (CY) 2006.
cData Source: Final Assessment Survey collected for CY 2009.
d1 = highest positive change; 10 = lowest positive change or highest negative change.
eH = high degree of change; L = low degree of change.
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spending patterns over time than others. As shown in
Table 4, sites ranged from investing as little as US$ 0.88
for every US$ 1 received from NCI (both matching and
donated costs) to as high as US$ 7.47, with an average
additional investment across all 3 years of US$ 4.14.
Association of co-investment with evidence of reaching
desired strategic goals
We explored whether there was an association be-
tween levels of co-investment and the extent to which
hospitals experienced changes in three strategic out-
comes identified during interviews with executives:
increases in Medicare market share, cancer patient
volume, and/or number of key cancer physicians. As
shown in Table 5, cancer patient volume seemed to be
more closely associated with total investments than
the other two outcomes, with four sites reporting the
highest degree of change in cancer patient volume
paired with the highest level of investments and four
other sites reporting the opposite (low volume and
low investments relative to other sites). There did not
seem to be an association between positive Medicare
market share change and investments. Findings spe-
cific to increases in number of key cancer physicians
are difficult to determine because all but one site
experienced an increase.
Table 3 Results of key cancer physician recruitment at baseline and follow-up of NCCCP implementation
Number of key cancer physiciansa
Site numberb Baseline (CY 2006)c Follow-up (CY 2009)d Change Ranking of change Degree of changee
Site 1 8 11 +3 8 L
Site 2 4 39 +35 1 H
Site 3 32 37 +5 5 H
Site 4 10 11 +1 9 L
Site 5 9 18 +9 3 H
Site 6 25 30 +5 5 H
Site 7 12 10 −2 10 L
Site 8 10 16 +6 4 H
Site 9 17 38 +19 2 H
Site 10 19 24 +5 5 H
aSites were asked to provide the “number and type of clinical staff” that “operate in the cancer centre [as of a given date] as noted in the definition provided.”
For this variable, sites were to indicate the number and type of staff such as medical oncologists, radiation oncologists, and clinical research nurses. From this
information, the number of physicians was extrapolated. The count presented excludes physician assistants, physicists, dosimetrists, therapists, technicians,
geneticists, phlebotomists, or any other role clearly not a physician.
bSites have been randomly numbered to ensure confidentiality of data.
cData Source: Baseline Assessment Survey (BAS) collected for Calendar Year (CY) 2006.
dData Source: FAS collected for CY 2009.
e1 = highest positive change; 10 = lowest positive change or highest negative change. Note that three hospitals reported a positive change of five additional key
cancer physicians so are ranked as ties, skewing the count to seven “high” ranked sites.
Table 4 Additional spending per dollar of total NCCCP funding, by site
Site Invoiced dollar
(US$)
Matching dollar
(US$)
Donated time dollar
(US$)
Total additional investment
(US$)
Rankinga Degree of change
Site 1 1.00 2.91 2.33 5.24 2 H
Site 2 1.00 3.05 0.52 3.57 5 H
Site 3 1.00 1.81 1.10 2.91 7 L
Site 4 1.00 0.84 0.04 0.88 10 L
Site 5 1.00 1.95 1.05 3.00 6 L
Site 6 1.00 1.18 0.05 1.23 9 L
Site 7 1.00 4.25 0.46 4.72 4 H
Site 8 1.00 6.06 1.41 7.47 1 H
Site 9 1.00 4.67 0.42 5.09 3 H
Site 10 1.00 2.35 0.12 2.46 8 L
Average, all sites 1.00 3.29 0.85 4.14
aRanking is across the sites, by total additional investments, from highest (1) to lowest (10).
Source: RTI Analysis of Completed Cost Assessment Tools, Years 1–3.
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Discussion
One of the most innovative aspects of the NCCCP is the
fact that it was established as a public-private partner-
ship between the federal government and numerous
not-for-profit hospitals [1,3]. With significant decreases
in funding from both the private and public sectors, the
need for such collaborations is paramount to improving
health quality while also reducing costs [1,3,24]. To
establish this partnership, NCI provided each selected
hospital with a relatively small amount of funding (ap-
proximately US$ 500,000 per year for each of the 10
funded sites), and any remaining resources needed to
meet NCCCP deliverables were required as matching or
donated funds from participating hospitals. Micro-cost
study findings indicate that, by the end of Year 3, on
average, for every US$ 1 provided by NCI, participating
hospitals had spent more than US$ 3 on NCCCP imple-
mentation. We were able to demonstrate that invest-
ments in cancer care and research appeared to be
associated with at least one of three strategic goals that
hospital executive management valued most from their
affiliation with NCI: increased cancer patient volume.
We were unable to demonstrate an association between
investments and changes in market share or recruitment
of key cancer physicians.
Increased cancer patient volume seemed to be the
outcome with the clearest association to total NCCCP
investments. This measurable change could be because
it is the outcome most likely to change in the shortest
period of time. Since the time period examined was only
three years, it is unlikely that sufficient time had passed
to expect a change to be demonstrated in data specific
to Medicare market share. Increases in key cancer physi-
cians affiliated with the participating hospitals were
reported for nine of the 10 lead sites. Because all but
two hospitals participating in the NCCCP pilot rely
primarily on private practice physicians, this increase
represents substantial growth, particularly for specific
hospitals (e.g. increases of as many as 19 or 35 physi-
cians). Without knowing the extent to which changes in
physician numbers had occurred prior to NCCCP, it is
impossible to link the program’s efforts to this particular
outcome. However, we know anecdotally that two subur-
ban hospitals recruited new cancer centre directors to
their areas who were also physicians with national
reputations as a direct result of being a NCCCP site, and
two rural hospitals and six suburban hospitals were able
to recruit subspecialists (e.g. breast surgeon, gynaeco-
logical oncologist) to their area for the first time. These
respondents, who were new to the hospital, shared in
interviews that the hospital’s partnership with NCI and
their clear commitment to the cancer service line were
the primary reasons they had opted to accept a position
there. In addition, most hospitals reported having more
physicians engaged in ongoing care coordination be-
cause of the extra efforts being made through NCCCP
implementation (e.g. multidisciplinary care conferences).
Although the NCCCP evaluation was a comprehen-
sive, mixed-method design, there are limitations to the
data used for the analyses that should be considered.
One obvious challenge is the limited number of sites, al-
though extensive data were collected and several sources
summarized for the 10 sites presented here. While find-
ings from the evaluation of the NCCCP are limited to a
sample size of these 10, our findings provide a unique
opportunity to assess whether public-private partner-
ships, as vehicles to leverage local investment, can mutu-
ally benefit NCI, the participating institutions, and the
communities they serve. Timing of data collection was
also a factor since presented data were collected at
slightly different points in time, making explanations of
findings challenging (e.g. cost data were collected at a
different time of year than interviews were conducted).
Another element of time that is important to consider is
that each hospital’s cancer program was in a different
phase of their development, with some being clear
leaders in their local markets at the start of NCCCP
while others were not. Similarly, some hospitals had fully
integrated cancer service lines with a medical director
and clinical trials program while others did not have that
capacity at the start. Therefore, we assessed the percent
change in each outcome for each individual hospital (i.e.
comparing their post-measure to their own pre-measure,
not comparing them to other hospitals) and rank
ordered them within two groups, producing a relatively
crude estimate of change over time. With a larger sam-
ple size, we would have been able to perform more
sophisticated analyses to explore patterns in investments
and the three outcomes. Finally, because all hospitals in
the study were participating in the NCCCP, and many
Table 5 Examination of the association between site total co-investments in NCCCP and changes in desired outcomes:
increased market share, cancer patient volume, and number of key cancer physicians
Total investments
(matching + donated costs)
Medicare market share
(change from year 1 to year 3)
Cancer patient volume
(change from year 1 to year 3)
Number of key cancer physicians
(change from year 1 to year 3)
Low High Low High Low High
Matching + Donated costs: LOW TOTAL 2 4 4 1 1 4
Matching + Donated: HIGH TOTAL 2 2 1 4 2 3
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were making other cancer care changes contemporaneous
to the program, full attribution of outcomes to the
NCCCP is not possible. Still, these findings provide a first
look at the motivations of hospital executives to commit
to programs such as the NCCCP, and the types of changes
that might be expected in a relatively short period of time.
Conclusions
The NCCCP was a pilot program implemented on a
relatively small scale (in 16 hospitals) to test the feasi-
bility of the concept of the NCCCP as a public-private
partnership to more quickly diffuse the rapidly chan-
ging science around cancer care into community
settings. The overall evaluation was intended to pro-
vide a formative evaluation of what seemed to work
well and what should be improved upon to enhance
the NCCCP model. In this way, the evaluation find-
ings, along with the program, had to evolve over time
because so many lessons were learned during each
phase of implementation.
The scientific landscape (e.g. advances in genomics),
healthcare reform, and policy and socioeconomic issues
all influenced the rationale for creating the NCCCP as a
public-private partnership [1]. NCI leveraged its funding
to fulfil important research goals through partnerships
with community hospitals. These partnerships benefited
the hospitals through their affiliations with NCI, and the
access to NCI staff and resources that these affiliations
afforded. In exchange, the NCI realized the benefits of
hospitals’ co-investments and efforts to support mutually
beneficial goals. The partnerships required collaboration
with the management of the participating hospitals,
since management controls the resources of the institu-
tion and must make decisions to navigate competitive
and policy-driven environments. Clinician participation
in the NCCCP was clearly important, but gaining and
sustaining hospitals’ commitment relied critically on the
existence of a strategic case for involvement in the
NCCCP. This took the form of expected patient volume
and market share increases, as well as enhanced oppor-
tunities for physician recruitment.
Our cost study shows that private investment in can-
cer service lines translated into an average of US$ 3 in
hospital funding for every US$ 1 provided by NCI. This
level of investment alone demonstrates how much of a
catalyst the NCCCP was in driving the hospitals to focus
on advancing science in their local areas. We have
reported elsewhere that the evaluation results indicate
that most of the participating hospitals were able to
expand their cancer programs and research infrastruc-
tures [13-16], increase evidence-based care [17], increase
physician engagement [18,19], and invest significant
matching funds [20]. However, with regards to execu-
tives’ reported strategic goals, this study showed that
levels of financial investment were only associated with
increases in cancer patient volume over the 3-year
period. Increasing market share may take more time as
it is highly dependent on the competitive environment.
Recruitment of key cancer physicians was seen across all
but one of the participating hospitals, regardless of levels
of matching investment. Results of qualitative interviews
suggest that physician recruitment may be driven more
by the NCI affiliation and the perceived commitment of
the hospital to cancer care, than by actual levels of
spending, at least in the short-term.
Importantly, implementation of the NCCCP occurred
within the context of the worst economic downturn
since the Great Depression, which added to the stress of
hospitals investing in this public-private partnership.
Moreover, it coincided with the early years of the
Affordable Care Act, when significant market shifts were
occurring and reimbursement methods were changing.
The multiple dimensions of the turbulent environment
faced by NCI, as well as the management and clinicians
in the participating community hospitals were a chal-
lenge. Yet, despite these challenges, the participating
hospitals found value sufficient to justify their invest-
ment, thus illustrating the potential of public-private
partnerships with aligned goals to leverage federal funds
to achieve important policy objectives.
In the years ahead, initiatives to advance value-based
care will increase given the major changes underway as
a result of the Affordable Care Act’s passage in 2009.
Based on the experience of the NCCCP, there is no
doubt that there is much that government can accom-
plish in collaboration with healthcare organizations to
manage disruptive change and to advance science and
improve healthcare in the community. Despite its small
sample size, the NCCCP evaluation provides an oppor-
tunity to document the lessons learned from the pro-
gram and ensure that future programs are informed by
these efforts. This study also contributes to existing
research on the business case for quality by expanding
the concept to the strategic case. Our study is a first step
in determining how to assess the ‘strategic case’ for such
a partnership, and helps to inform the types of outcomes
that can realistically be expected to occur in a relatively
short time-frame. Still, more needs to be understood
about how best to facilitate these public-private partner-
ships and under what circumstances they lead to out-
comes desired by all partners involved.
Availability of supporting data
The data set(s) supporting results of this article and
collected from the participating hospitals are not avail-
able due to constraints of our Data Use Agreements.
Medicare market share data are readily available via
www.cms.gov (Accessed 10-1-15).
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Endnotes
aFor more details on the methods and data sources
used in the overall evaluation, see [12].
bFor more details on the micro-cost study methodology,
see [20].
cNote that the baseline patient volume count for
calendar year 2006 was provided by sites in their initial
proposals for funding.
dAvailable from the Centers for Medicare & Medicaid
Services
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